Ariad aims for global oncology play as it files US ponatinib NDA in CML
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals is ahead of schedule with its plans to take on the $4.5 billion chronic myeloid leukaemia market. Ponatinib is key to Ariad's plans to transform itself from an innovative discovery and development enterprise to a global oncology business (scripintelligence.com, 5 June 2012).